Jerome Lozada, Helen Merkens, Juliette Froelich, Ruyin Astoria Tai, Kuo-Shyan Lin, François Bénard and David M. Perrin*,
{"title":"靶向PSMA的双模18F-PET荧光示踪剂的合成及临床前评价","authors":"Jerome Lozada, Helen Merkens, Juliette Froelich, Ruyin Astoria Tai, Kuo-Shyan Lin, François Bénard and David M. Perrin*, ","doi":"10.1021/acs.jmedchem.5c01480","DOIUrl":null,"url":null,"abstract":"<p >Dual-mode fluorescent PET tracers for imaging prostate cancer hold promise for coordinating preoperative PET imaging with intraoperative surgical imaging applications. Here, we disclose two PET tracers containing three key design elements: (1) an organotrifluoroborate for one-step radiofluorination at Curie levels of [<sup>18</sup>F] fluoride in good yields and high molar activity (A<sub>m</sub>) values: 42–167 GBq/μmol, (2) two fluorescein moieties (FAM and FITC) for fluorescent visualization, and (3) two pharmacophores based on clinically validated scaffolds PSMA-617 and PSMA-1007. These tracers are the first-ever examples of dual-mode PSMA-targeting agents that are labeled with both fluorescein and fluorine-18. Both were evaluated using LNCaP and 22Rv1 xenografts and show high tumor uptake (7–17% ID/g), strong fluorescent visualization on cultured LNCaP and 22Rv1 cells, and fluorescence detection <i>ex vivo</i>. These results highlight the potential of PSMA-targeting dual-mode tracers for clinical translation in PET imaging, surgical navigation, fluorescence-guided surgery (FGS), and radioguided surgery (RGS).</p>","PeriodicalId":46,"journal":{"name":"Journal of Medicinal Chemistry","volume":"68 15","pages":"16645–16665"},"PeriodicalIF":6.8000,"publicationDate":"2025-07-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Synthesis and Preclinical Evaluation of Dual-Mode Fluorescent 18F-PET Tracers Targeting PSMA\",\"authors\":\"Jerome Lozada, Helen Merkens, Juliette Froelich, Ruyin Astoria Tai, Kuo-Shyan Lin, François Bénard and David M. Perrin*, \",\"doi\":\"10.1021/acs.jmedchem.5c01480\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p >Dual-mode fluorescent PET tracers for imaging prostate cancer hold promise for coordinating preoperative PET imaging with intraoperative surgical imaging applications. Here, we disclose two PET tracers containing three key design elements: (1) an organotrifluoroborate for one-step radiofluorination at Curie levels of [<sup>18</sup>F] fluoride in good yields and high molar activity (A<sub>m</sub>) values: 42–167 GBq/μmol, (2) two fluorescein moieties (FAM and FITC) for fluorescent visualization, and (3) two pharmacophores based on clinically validated scaffolds PSMA-617 and PSMA-1007. These tracers are the first-ever examples of dual-mode PSMA-targeting agents that are labeled with both fluorescein and fluorine-18. Both were evaluated using LNCaP and 22Rv1 xenografts and show high tumor uptake (7–17% ID/g), strong fluorescent visualization on cultured LNCaP and 22Rv1 cells, and fluorescence detection <i>ex vivo</i>. These results highlight the potential of PSMA-targeting dual-mode tracers for clinical translation in PET imaging, surgical navigation, fluorescence-guided surgery (FGS), and radioguided surgery (RGS).</p>\",\"PeriodicalId\":46,\"journal\":{\"name\":\"Journal of Medicinal Chemistry\",\"volume\":\"68 15\",\"pages\":\"16645–16665\"},\"PeriodicalIF\":6.8000,\"publicationDate\":\"2025-07-30\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Medicinal Chemistry\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://pubs.acs.org/doi/10.1021/acs.jmedchem.5c01480\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"CHEMISTRY, MEDICINAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Medicinal Chemistry","FirstCategoryId":"3","ListUrlMain":"https://pubs.acs.org/doi/10.1021/acs.jmedchem.5c01480","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CHEMISTRY, MEDICINAL","Score":null,"Total":0}
Synthesis and Preclinical Evaluation of Dual-Mode Fluorescent 18F-PET Tracers Targeting PSMA
Dual-mode fluorescent PET tracers for imaging prostate cancer hold promise for coordinating preoperative PET imaging with intraoperative surgical imaging applications. Here, we disclose two PET tracers containing three key design elements: (1) an organotrifluoroborate for one-step radiofluorination at Curie levels of [18F] fluoride in good yields and high molar activity (Am) values: 42–167 GBq/μmol, (2) two fluorescein moieties (FAM and FITC) for fluorescent visualization, and (3) two pharmacophores based on clinically validated scaffolds PSMA-617 and PSMA-1007. These tracers are the first-ever examples of dual-mode PSMA-targeting agents that are labeled with both fluorescein and fluorine-18. Both were evaluated using LNCaP and 22Rv1 xenografts and show high tumor uptake (7–17% ID/g), strong fluorescent visualization on cultured LNCaP and 22Rv1 cells, and fluorescence detection ex vivo. These results highlight the potential of PSMA-targeting dual-mode tracers for clinical translation in PET imaging, surgical navigation, fluorescence-guided surgery (FGS), and radioguided surgery (RGS).
期刊介绍:
The Journal of Medicinal Chemistry is a prestigious biweekly peer-reviewed publication that focuses on the multifaceted field of medicinal chemistry. Since its inception in 1959 as the Journal of Medicinal and Pharmaceutical Chemistry, it has evolved to become a cornerstone in the dissemination of research findings related to the design, synthesis, and development of therapeutic agents.
The Journal of Medicinal Chemistry is recognized for its significant impact in the scientific community, as evidenced by its 2022 impact factor of 7.3. This metric reflects the journal's influence and the importance of its content in shaping the future of drug discovery and development. The journal serves as a vital resource for chemists, pharmacologists, and other researchers interested in the molecular mechanisms of drug action and the optimization of therapeutic compounds.